pralsetinib
Rigel Pharma Acquires US Rights to Blueprint Medicines' Gavreto
Blueprint regained rights to Gavreto this year after Roche ended its collaboration agreement for the drug.
FDA Converts Gavreto Accelerated Approval to Full Approval in RET Fusion-Positive NSCLC
The agency granted full approval to Roche and Blueprint Medicine's RET inhibitor based on data from additional patients enrolled on the ARROW trial.
Roche, Blueprint Medicines Withdraw Gavreto in RET-Mutant Medullary Thyroid Cancer in US
Genentech has decided it will no longer pursue the confirmatory trial for Gavreto in this setting due to feasibility.
Roche to Terminate Gavreto Deal With Blueprint Medicines
Blueprint will regain global commercialization rights for the RET inhibitor following Roche's decision to end the collaboration for strategic reasons.
Blueprint Medicines Inks $1.25B Financing Deal in Exchange for Royalties of Ayvakit, Gavreto
Sixth Street is providing funds in exchange for future royalties of Ayvakit and the KIT D816V inhibitor BLU-263, while Royalty Pharma inked a similar deal for Gavreto.